Suppr超能文献

脂质纳米载体的聚乙二醇化或壳聚糖化表面修饰对阿哌沙班体内药代动力学/药效学特征的影响。

Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban.

作者信息

Zaky Mohamed F, Hammady Taha M, Gad Shadeed, Alattar Abdullah, Alshaman Reem, Hegazy Ann, Zaitone Sawsan A, Ghorab Mamdouh Mostafa, Megahed Mohamed A

机构信息

Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Egyptian Russian University, Cairo 11829, Egypt.

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt.

出版信息

Pharmaceutics. 2023 Jun 7;15(6):1668. doi: 10.3390/pharmaceutics15061668.

Abstract

Nanostructured lipid carriers (NLCs) have been proven to significantly improve the bioavailability and efficacy of many drugs; however, they still have many limitations. These limitations could hinder their potential for enhancing the bioavailability of poorly water-soluble drugs and, therefore, require further amendments. From this perspective, we have investigated how the chitosanization and PEGylation of NLCs affected their ability to function as a delivery system for apixaban (APX). These surface modifications could enhance the ability of NLCs to improve the bioavailability and pharmacodynamic activity of the loaded drug. In vitro and in vivo studies were carried out to examine APX-loaded NLCs, chitosan-modified NLCs, and PEGylated NLCs. The three nanoarchitectures displayed a Higuchi-diffusion release pattern in vitro, in addition to having their vesicular outline proven via electron microscopy. PEGylated and chitosanized NLCs retained good stability over 3 months, versus the nonPEGylated and nonchitosanized NLCs. Interestingly, APX-loaded chitosan-modified NLCs displayed better stability than the APX-loaded PEGylated NLCs, in terms of mean vesicle size after 90 days. On the other hand, the absorption profile of APX (AUC) in rats pretreated with APX-loaded PEGylated NLCs (108.59 µg·mL·h) was significantly higher than the AUC of APX in rats pretreated with APX-loaded chitosan-modified NLCs (93.397 µg·mL·h), and both were also significantly higher than AUC of APX-Loaded NLCs (55.435 µg·mL·h). Chitosan-coated NLCs enhanced APX anticoagulant activity with increased prothrombin time and activated partial thromboplastin time by 1.6- and 1.55-folds, respectively, compared to unmodified NLCs, and by 1.23- and 1.37-folds, respectively, compared to PEGylated NLCs. The PEGylation and chitosanization of NLCs enhanced the bioavailability and anticoagulant activity of APX over the nonmodified NLCs; this highlighted the importance of both approaches.

摘要

纳米结构脂质载体(NLCs)已被证明能显著提高许多药物的生物利用度和疗效;然而,它们仍有许多局限性。这些局限性可能会阻碍其提高难溶性药物生物利用度的潜力,因此需要进一步改进。从这个角度来看,我们研究了NLCs的壳聚糖化和聚乙二醇化如何影响其作为阿哌沙班(APX)递送系统的功能。这些表面修饰可以增强NLCs提高所载药物生物利用度和药效学活性的能力。进行了体外和体内研究,以考察载有APX的NLCs、壳聚糖修饰的NLCs和聚乙二醇化的NLCs。这三种纳米结构在体外呈现出 Higuchi 扩散释放模式,此外还通过电子显微镜证实了它们的囊泡轮廓。与未聚乙二醇化和未壳聚糖化的NLCs相比,聚乙二醇化和壳聚糖化的NLCs在3个月内保持了良好的稳定性。有趣的是,就90天后的平均囊泡大小而言,载有APX的壳聚糖修饰的NLCs比载有APX的聚乙二醇化的NLCs表现出更好的稳定性。另一方面,用载有APX的聚乙二醇化NLCs预处理的大鼠中APX的吸收曲线(AUC)(108.59 µg·mL·h)显著高于用载有APX的壳聚糖修饰的NLCs预处理的大鼠中APX的AUC(93.397 µg·mL·h),并且两者也均显著高于载有APX的NLCs的AUC(55.435 µg·mL·h)。与未修饰的NLCs相比,壳聚糖包被的NLCs使APX的抗凝活性增强,凝血酶原时间和活化部分凝血活酶时间分别增加了1.6倍和1.55倍,与聚乙二醇化的NLCs相比,分别增加了1.23倍和1.37倍。NLCs的聚乙二醇化和壳聚糖化相对于未修饰的NLCs提高了APX的生物利用度和抗凝活性;这突出了这两种方法的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d27/10302406/22cf24ffdc5d/pharmaceutics-15-01668-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验